By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.

Catalent and Novo Holdings

Unlocking Greater Value, Together

Transaction Overview

Catalent has entered into an agreement to be acquired by Novo Holdings, a global investment firm focused on life sciences. Following the close of the transaction, Catalent will benefit from Novo Holdings’ significant resources, and will be well-positioned to accelerate its strategy to create value for stakeholders, ultimately delivering better outcomes for customers and patients they serve.

A Global Life Sciences and Healthcare Investment Firm

Novo Holdings is a global life sciences and healthcare investment firm. In addition to its life sciences investments across subsectors, it has a diversified portfolio of equities, credit, real estate and infrastructure assets.

Our Commitment

To continue to build and leverage an ecosystem that enables innovation to deliver better patient outcomes.

Quality Pharma Services

As a major pharma services company, Catalent enables its global pharma, biotech, and consumer health partners to optimize their own operations – starting with product development through to product launch and full life-cycle supply.

A Global Leading CDMO
Catalent
+
Novo Holdings

Novo Holdings to acquire Catalent

As announced on February 5, 2024

On May 29, 2024, Catalent stockholders voted to approve the pending transaction

The transaction is expected to close towards the end of calendar year 2024, subject to customary closing conditions and receipt of required regulatory approvals

At that time, Catalent will become a private company continuing to focus on its mission of enabling the development and supply of better treatments for patients worldwide

In a separate transaction that will occur post-close, Novo Holdings intends to sell three of Catalent’s 50+ global sites located in Anagni, Italy; Bloomington, Indiana USA; and Brussels, Belgium to Novo Nordisk

Catalent’s 50+ global sites

Novo Nordisk
Post-close, Novo Holdings intends to sell three of Catalent’s 50+ sites located in Anagni, Italy; Bloomington, Indiana USA; and Brussels, Belgium and related assets to Novo Nordisk.
Novo Nordisk operates separately from Novo Holdings.
“Catalent will remain a leading global service provider to the biotech and pharmaceutical industries, following the completion of the transaction with Novo Holdings. Under private ownership, we will benefit from access to additional capital and resources to provide enhanced service for the benefit of customers and patients. Catalent is a Patient First organization with a mission to develop, manufacture and supply products that help people live better and healthier lives – and this will remain our top priority.”
Photo of Alessandro Maselli, President and Chief Executive Officer of Catalent, Inc.
Alessandro Maselli
President and Chief Executive Officer of Catalent, Inc.
“We are excited to partner with Catalent as it enters a new phase of growth and accelerates its mission to develop, manufacture and supply products that help people live better and healthier lives. With our expertise and track record of investing in high quality life sciences businesses, we believe Catalent is a very good strategic fit. We are excited to support the Company’s stakeholders in the years ahead, especially employees and customers as they work to develop new products to benefit patients. As engaged investors committed to productive relationships with all our partners, we look forward to working with the Catalent team to realise the Company’s full potential.”
Photo of Kasim Kutay, CEO of Novo Holdings
Kasim Kutay
CEO of Novo Holdings

Transaction Resources

DECEMBER 6, 2024
Catalent and Novo Holdings Receive European Commission Unconditional Approval for Pending Transaction
Download PDF
October 21, 2024
Catalent Issues Open Letter to Customers Regarding Pending Acquisition by Novo Holdings
Download PDF
October 17, 2024
Novo Holdings Company Statement
Download PDF
October 14, 2024
Catalent Company Statement
Download PDF
July 15, 2024
Endpoints Article: CDMO’s Critical Role in a Rapidly Evolving Biopharma Landscape
Read Article
July 15, 2024
Endpoints Article: CDMO’s Critical Role in a Rapidly Evolving Biopharma Landscape
Read Article
July 15, 2024
Endpoints Webinar with Catalent CEO Alessandro Maselli
Watch Video
May 29, 2024
Special Meeting Results Press Release
Download PDF
February 5, 2024
Transaction Announcement Press Release
Download PDF
February 5, 2024
Novo Nordisk Fill-finish Site Transaction Announcement Press Release
Download PDF
Transaction Factsheet
Download PDF